Literature DB >> 7501578

Chronic stable angina pectoris. Strategies for effective drug therapy.

U Thadani1, A Chohan.   

Abstract

In most patients with stable angina pectoris, severe eccentric atherosclerotic narrowing of coronary arteries is responsible for chest pain and myocardial ischemia. If myocardial infarction or death occurs, it is usually the consequence of a ruptured plaque. About 10% to 20% of patients with stable angina have normal coronary arteries, and their long-term prognosis is excellent. In patients with angina secondary to atherosclerotic lesions, the annual mortality rate is 1.6% to 3.2%; prognosis is determined by systolic left ventricular function and the extent of coronary artery disease. Patients can be stratified into low- and high-risk groups by medical history, left ventricular function at rest, and results of physical examination and stress testing. Coronary angiography should be reserved for high-risk patients. Risk-factor modification and appropriate use of antianginal drugs are successful in most patients, but those who fail to respond should be considered for angioplasty or coronary bypass surgery; patients with left main coronary artery disease or three-vessel disease and poor left ventricular function should be considered for coronary artery bypass surgery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7501578

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

Review 1.  Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.

Authors:  N S Gunasekara; S Noble
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 2.  Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.

Authors:  R N Brogden; A Markham
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

3.  [Not Available].

Authors:  B Debrégeas; J Duchier
Journal:  Clin Drug Investig       Date:  1997       Impact factor: 2.859

Review 4.  Choosing the most appropriate treatment for stable angina. Safety considerations.

Authors:  S Asirvatham; C Sebastian; U Thadani
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.